The emerging role of PET imaging in dementia
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
A compelling need in the field of neurodegenerative diseases is the development and validation of biomarkers for early identification and differential diagnosis. The availability of positron emission tomography (PET) neuroimaging tools for the assessment of molecular biology and neuropathology has opened new venues in the diagnostic design and the conduction of new clinical trials. PET techniques, allowing the in vivo assessment of brain function and pathology changes, are increasingly showing great potential in supporting clinical diagnosis also in the early and even preclinical phases of dementia. This review will summarize the most recent evidence on fluorine-18 fluorodeoxyglucose-, amyloid -, tau -, and neuroinflammation - PET tools, highlighting strengths and limitations and possible new perspectives in research and clinical applications. Appropriate use of PET tools is crucial for a prompt diagnosis and target evaluation of new developed drugs aimed at slowing or preventing dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · cited 1×
“Standardization of acquisition procedures and data analysis will certainly improve the incorporation of amyloid-PET biomarkers into the standard diagnostic criteria for AD 3,5,7 .”
MethodThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 2×
“Tau protein can present in six different isoforms, which are grouped on the basis of the number of microtubule-binding domain repeats (that is, three or four (3R/4R)) 110 .”
BackgroundNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“The first tau PET imaging results in the AD spectrum have provided compelling evidence for a tight relationship between tau burden and synaptic dysfunction, gray matter atrophy, and cognitive deficits 117–120 , confirming previous post-mortem evidence 121,122 .”
BackgroundHow neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 2×
“Crucially, it remains to be understood whether this local immune response is thoroughly beneficial or rather can promote neuro-degeneration 149 .”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“The majority of clinical trials in AD have focused on amyloid therapies (for example, see references 96–98), also including serial amyloid-PET scans to evaluate decreases in cerebral amyloid burden 97,98 .”
BackgroundCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“In neurodegenerative conditions, microglia can acquire very diverse functional phenotypes based upon several factors 189 ; in this direction, the development of PET radioligands with particular affinity for specific microglial polarizations (for instance, homeostatic versus neurotoxic) would be of…”
BackgroundThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 4×
“Multiple reports showed a cross-sectional association between worsening of cognitive impairment and increasing cortical tau-PET binding, from normal cognition to MCI and AD dementia stages 117,118,120 .”
BackgroundInfluentialIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · cited 2×
“Several studies specifically focused on the relationships between tau and amyloid accumulation in AD and in healthy aging 119,120,129–133 .”
Background(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · cited 1×
“Multiple reports showed a cross-sectional association between worsening of cognitive impairment and increasing cortical tau-PET binding, from normal cognition to MCI and AD dementia stages 117,118,120 .”
BackgroundLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Owen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 3×
“The introduction of tau-PET techniques is reshaping the AD research field, allowing a more targeted evaluation of the original amyloid cascade hypothesis, which remains highly controversial (see “Amyloid PET” section above and 67,128 ).”
BackgroundMethodMaruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“To date, three broad groups of radioligands are under extensive evaluation: the 18 F-THK5351, 18 F-THK5117, or 18 F-THK5105 112–114 ; the 18 F-T807 (also known as 18 F-AV1451 or 18 F-Flortaucipir) 115 ; and the 11 C-PBB3 116 .”
BackgroundMarquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602 · cited 1×
“Both 11 C-PiB and 18 F-labelled amyloid-PET tracers bind with high affinity to fibrillar amyloid in neuritic plaques 62–65 .”
BackgroundHamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 4×
“When agglomerating, hyperphosphorylated tau can additionally assume different conformations, such as paired helical filaments (PHFs), straight filaments, and irregular filaments 109 .”
BackgroundInfluentialIn vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · cited 2×
“Another area of concern regards consistent non-specific tau-PET binding in subcortical structures, especially in the striatum and in the choroid plexus, in healthy controls, suggesting that the currently available tau tracers could present off-target binding, such as to neuromelanin 137,138 .”
BackgroundCarter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Brain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · cited 1×
“However, since amyloid deposition rate increases rapidly in the prodromal phases of the disease 74 , in some subjects it might have already reached a plateau in the MCI stage 22 .”
BackgroundDirect neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism
Lundgaard, I., Li, B., Xie, L., Kang, H., Sanggaard, S., Haswell, J. D. R., Sun, W., Goldman, S., Blekot, S., Nielsen, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7807 · Cited by 381
Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)
Dickson, D. W., Kouri, N., Murray, M. E., & Josephs, K. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9589-0 · Cited by 380
Venneti, S., Lopresti, B. J., & Wiley, C. A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.10.002 · Cited by 373
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
[18F]FDG PET signal is driven by astroglial glutamate transport
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience · doi:10.1038/nn.4492 · Cited by 343
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · cited 3×
“It should be taken into account that the characteristics of 18 F-FDG-PET hypometabolic patterns in MCI individuals can indicate the prognostic risk of progression to different dementia conditions (see above) 23–25 , In patients with dementia, amyloid PET is recognized as a powerful tool to differentiate conditions cha…”
BackgroundNeuroinflammation in Neurodegenerative Disorders-a Review
Schain, M., & Kreisl, W. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0733-2 · Cited by 301
Mild cognitive impairment due to Alzheimer disease in the community
Petersen, R. C., Aisen, P., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Knopman, D. S., Mielke, M., Pankratz, V. S., Roberts, R., Rocca, W. A., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23931 · Cited by 265
Noninvasive Molecular Imaging of Neuroinflammation
Jacobs, A. H., Tavitian, B., & the INMiND consortium (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.53 · Cited by 245
The methodology of TSPO imaging with positron emission tomography
Turkheimer, F. E., Rizzo, G., Bloomfield, P. S., Howes, O., Zanotti-Fregonara, P., Bertoldo, A., & Veronese, M. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150058 · Cited by 238 · cited 2×
“Of note, quantification of TSPO PET can be particularly challenging 159 given the intrinsic characteristics of the TSPO protein 159 .”
BackgroundBrain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236 · cited 1×
“…to be a direct index of synaptic dysfunction, which can result from a variety of neuropathological events, including but not limited to altered intracellular signaling cascades and mitochondria bioenergetics, impaired neurotransmitter release, and accumulation of neurotoxic protein species 9,19 .”
BackgroundIannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221
Self-citationFan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212 · cited 1×
“As for other neurodegenerative conditions, TSPO PET has been successfully applied in synucleinopathies, such as in DLB, PD, and PD with dementia 173–175 ; in FTD 176 ; in atypical parkinsonisms such as multiple system atrophy (MSA), CBD, and PSP 177–179 ; and in prion diseases, such as…”
BackgroundIn vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187 · cited 3×
“It should be taken into account that the characteristics of 18 F-FDG-PET hypometabolic patterns in MCI individuals can indicate the prognostic risk of progression to different dementia conditions (see above) 23–25 , In patients with dementia, amyloid PET is recognized as a powerful tool to differentiate conditions cha…”
MethodSander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., Schott, J. M., Revesz, T., Fox, N. C., & Årstad, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.003 · Cited by 187
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186 · cited 1×
“Of note, in MCI, recent studies have shown that risk to convert to AD is greater in amyloid-positive subjects 72 and that the time of conversion from MCI to AD dementia negatively correlates with the annual increase in amyloid deposition rate 73 .”
Self-citationDupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182 · cited 4×
“These second-generation ligands come with both 11 C or 18 F isotopes, such as 11 C-PBR28 and 18 F-DPA714, and overall display higher binding affinities 155 .”
BackgroundInfluentialYokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1612-0 · Cited by 174 · cited 1×
“Diverging evidence also exists regarding the association between microglia activation and amyloid burden 168–170 .”
BackgroundIn vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
Gerhard, A., Trender‐Gerhard, I., Turkheimer, F., Quinn, N. P., Bhatia, K. P., & Brooks, D. J. (2006) · Movement Disorders · doi:10.1002/mds.20668 · Cited by 171
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
Roberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143 · cited 1×
“89 , a long follow-up might be necessary to observe development of dementia, and up to 19 years might be needed to reach the mean value of amyloid observed in AD 90 .”
BackgroundFluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140
Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015) · Brain · doi:10.1093/brain/awv288 · Cited by 135 · cited 2×
“An increase of microglia activation in AD was longitudinally associated with amyloid accumulation and reductions of brain glucose metabolism 171 .”
BackgroundJosephs, K. A., Whitwell, J. L., Tacik, P., Duffy, J. R., Senjem, M. L., Tosakulwong, N., Jack, C. R., Lowe, V., Dickson, D. W., & Murray, M. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1618-1 · Cited by 127
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Cerami, C., Della Rosa, P. A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S. F., & Perani, D. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.12.004 · Cited by 127
Self-citationAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13164 · Cited by 92
Translational neuroimaging: positron emission tomography studies of monoamine oxidase
Fowler, J. S., Logan, J., Volkow, N. D., & Wang, G.-J. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0016-1 · Cited by 81 · cited 1×
“Astrocytosis can be uniquely measured through PET and the 11 C-deuterium-L-deprenyl ligand ( 11 C-DED), which is an irreversible inhibitor of the MAO-B enzyme, over-expressed during astrocyte activation 150 .”
BackgroundChételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80 · cited 1×
“Still, appropriate use criteria for amyloid-PET imaging stress the high accuracy of amyloid PET in ruling out AD 69 and in supporting AD dementia diagnosis, especially in three main clinical populations: (i) subjects with MCI, (ii) patients with suspected AD but atypical presentation or…”
BackgroundSeo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives
On behalf of the European Association of Nuclear Medicine, Morbelli, S., Garibotto, V., Van De Giessen, E., Arbizu, J., Chételat, G., Drezgza, A., Hesse, S., Lammertsma, A. A., Law, I., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3098-2 · Cited by 61
Iaccarino, L., Crespi, C., Della Rosa, P. A., Catricalà, E., Guidi, L., Marcone, A., Tagliavini, F., Magnani, G., Cappa, S. F., & Perani, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120197 · Cited by 56
Self-citation
Cited by
Iaccarino, L., Sala, A., Caminiti, S. P., Presotto, L., Perani, D., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190954 · Cited by 40
Self-citationClozapine induces astrocyte-dependent FDG-PET hypometabolism
Rocha, A., Bellaver, B., Souza, D. G., Schu, G., Fontana, I. C., Venturin, G. T., Greggio, S., Fontella, F. U., Schiavenin, M. L., Machado, L. S., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05682-3 · Cited by 31
Visser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“This has proven invaluable in providing insights for differential diagnostics and therapeutic monitoring (Carson et al., 2022; Dierckx et al., 2021; Herholz et al., 2007; Iaccarino et al., 2017; Topcuoglu et al., 2022a; van Waarde et al., 2021).”
BackgroundUsing diffusion tensor imaging to detect cortical changes in fronto-temporal dementia subtypes
Torso, M., Bozzali, M., Cercignani, M., Jenkinson, M., & Chance, S. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68118-8 · Cited by 27
Metadata
- Authors
- Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2017-10-12
- Volume
- 6
- Pages
- 1830
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W2762309236
- Cited by
- 50
- References
- 72
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.